In the last trading session, 1.05 million KalVista Pharmaceuticals Inc (NASDAQ:KALV) shares changed hands as the company’s beta touched 0.79. With the company’s per share price at $10.77 changed hands at $0.42 or 4.11% during last session, the market valuation stood at $532.48M. KALV’s last price was a discount, traded about -43.92% off its 52-week high of $15.50. The share price had its 52-week low at $7.30, which suggests the last value was 32.22% up since then.
Analysts gave the KalVista Pharmaceuticals Inc (KALV) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended KALV as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. KalVista Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.87.
KalVista Pharmaceuticals Inc (NASDAQ:KALV) trade information
Instantly KALV was in green as seen at the end of in last trading. With action 10.17%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 27.21%, with the 5-day performance at 10.17% in the green. However, in the 30-day time frame, KalVista Pharmaceuticals Inc (NASDAQ:KALV) is 25.15% up.
The consensus price target for the stock as assigned by Wall Street analysts is 20, meaning bulls need an upside of 46.15% from its current market value. According to analyst projections, KALV’s forecast low is 20 with 28 as the target high. To hit the forecast high, the stock’s price needs a -159.98% plunge from its current level, while the stock would need to soar -85.7% for it to hit the projected low.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -20.06%. The 2025 estimates are for KalVista Pharmaceuticals Inc earnings to decrease by -4.83%, but the outlook for the next 5-year period is at 29.77% per year.
KALV Dividends
KalVista Pharmaceuticals Inc is expected to release its next quarterly earnings report in March.
TANG CAPITAL MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 9.1252% or 4.22 million shares worth $49.7 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Smallcap World Fund and Vanguard Total Stock Market Index Fund . With 3.37 shares estimated at $36.36 million under it, the former controlled 6.83% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.43% of the shares, roughly 1.2 shares worth around $12.93 million.
